Synapse - Margaret Callahan

Results (197)

Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling

Journal Article

Cheng, A. P.; Widman, A. J.; Arora, A.; Rusinek, I.; Sossin, A.; Rajagopalan, S.; Midler, N.; Hooper, W. F.; Murray, R. M.; Halmos, D.; more...
Nature Methods (2025)

Fulltext@MSK | Save

Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors

Journal Article

Nykaza, I.; Murciano-Goroff, Y. R.; Desilets, A.; Harada, G.; Postow, M. A.; Callahan, M. K.; Lee, C. H.; Rudin, C. M.; Kelsen, D. P.; Stadler, Z. K.; more...
The Oncologist (2025)

Fulltext@MSK | Save

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

Journal Article

Ascierto, P. A.; Tang, H.; Dolfi, S.; Nyakas, M.; Marie Svane, I.; Muñoz-Couselo, E.; Grob, J. J.; Gomez-Roca, C. A.; Chiarion-Sileni, V.; Peltola, K.; more...
Journal for ImmunoTherapy of Cancer (2025)

Fulltext@MSK | Save

Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab

Journal Article

Lochrin, S. E.; Buonocore, D. J.; Young, R. J.; Kaley, T. J.; Postow, M. A.; Wolchok, J. D.; Shoushtari, A. N.; Momtaz, P.; Betof Warner, A. S.; Callahan, M. K.
Pigment Cell & Melanoma Research (2024)

Fulltext@MSK | Save

Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO)

Meeting Abstract

Gupta, A.; Whiting, K.; Keegan, N. M.; Schmalz, J.; Al-Ahmadie, H. A.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Iyer, G.; Rosenberg, J. E.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Early on-treatment assessment of T cells, cytokines, and tumor DNA with adaptively dosed nivolumab + ipilimumab: Final results from the phase 2 ADAPT-IT study

Journal Article

Smithy, J. W.; Kalvin, H. L.; Ehrich, F. D.; Shah, R.; Adamow, M.; Raber, V.; Maher, C. A.; Kleman, J.; McIntyre, D. A. G.; Shoushtari, A. N.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment

Journal Article

Widman, A. J.; Shah, M.; Frydendahl, A.; Halmos, D.; Khamnei, C. C.; Øgaard, N.; Rajagopalan, S.; Arora, A.; Deshpande, A.; Hooper, W. F.; more...
Nature Medicine (2024)

Fulltext@MSK | Save

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: Active drug monitoring to assess the impact of immune response on drug exposure

Journal Article

Spreafico, A.; Couselo, E. M.; Irmisch, A.; Bessa, J.; Au-Yeung, G.; Bechter, O.; Svane, I. M.; Sanmamed, M. F.; Gambardella, V.; McKean, M.; more...
Frontiers in Oncology (2024)

Fulltext@MSK | Save

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)